Bronchiolitis obliterans syndrome and other allo-reactive lung syndromes after allogeinic hematopoietic stem cell transplantation Is early prediction of bronchiolitis obliterans possible by using biomarkers possible?

Bronchiolitis obliterans syndrome and other allo-reactive lung syndromes after allogeinic hematopoietic stem cell transplantation Is early prediction of bronchiolitis obliterans possible by using biomarkers possible? - Bronchiolitis obliterans after hematopoietic stem cell transplantation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44102

Enrollment

360

Registered

2013-02-19

Start date

2013-12-03

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

afstoting na beenmergtransplantatie chronic lung rejection bronchiolitis obliterans lung rejection after hematopoietic stemcell transplantation

Interventions

None listed

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients whom are selected for hematopoietic stem cell transplantation

Exclusion criteria

Exclusion criteria: no informed consent all patients after hematopoietic stem cell transplantation will be included except patients that do not want to participate in this study.

Design outcomes

Primary

Measure	Time frame
Identifying biomarkers in the peripheral blood that predict BOS by a sgnificant elevation before a lungfunction decline occurs (i.e. a drop in FEV1 of 20%) after allogeneic hemtopoietic stem cell transplantation. .	—

Secondary

Measure	Time frame
To determine the incidence and outcome of allo-reactive lung syndromes (i.e. BOS and other ARLS) in patients that underwent allogeneic haematopoietic stem cell transplantation.	—

Countries

Netherlands

Outcome results